Biotechnology: personal care market report
The first in our biotechnology report series, reports that help other forward-thinking companies leverage the opportunities offered by biotechnology.Read the full report
Smart science to improve lives™
The delivery of innovation and the creation of new technologies are two key parts of our strategic approach to growth.
We offer a wide portfolio of innovative, sustainable and high performance ingredients for fast-growing and niche consumer and health care markets.
Health care investor seminar
We are hosting an investor seminar on our Health Care business on 7 October 2022. The in-person event will start at 08.30 BST, while the webcast of the event will begin at 09.30 BST. To register for the webcast, please use the registration button below. The live event has restricted capacity, however, if you would like to express an interest in attending in-person please contact email@example.com
Reduction in scope 1 and 2 emissions intensity since 202027.0%
Hectares of land saved above our 2019 baseline33,734.0
Organic raw materials from bio-based sources69.0%
People protected through use of our sun protection ingredients55.0million people
Knowledge, passion and can-do spirit
Our culture and behaviours are shaped and brought to life by the three guiding values of ‘Responsible’ ‘Innovative’, and ‘Together’.
We will be the most sustainable supplier of innovative ingredients, our action plan for the decade is to be Climate, Land and People Positive by 2030.Find out more
Non-financial performance and reports
We consider our non-financial metrics to be as important as our financial.Find out more
We are the name behind high performance ingredients and technologies in some of the most successful brands in the world.Find out more
Sustainability expert Aris Vrettos joins Croda
The new position will see the sustainability expert challenge Croda to stretch its already industry-leading sustainability ambitions and commitments and support Croda’s business sectors in further...Read more
UK Government to support expansion of Croda's lipid systems manufacturing facility
31 March 2022: This investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines.Read more
U.S. Government to support expansion of Croda lipid systems capability
Today we announce a joint investment with the U.S. government to expand our U.S manufacturing capacity for lipid systems used in novel therapeutic drugs, such as mRNA vaccinesRead more